A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Remibrutinib Impurity 40 - Request Quote

Picture of Remibrutinib Impurity 40

Remibrutinib Impurity 40

SZ CAT No:SZ-R098044
CAS No
NA
Mol.F.
C17H14BrF2NO
Mol.Wt.
366.2
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Remibrutinib Impurity 40 is chemically N-(4-Bromo-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide. Remibrutinib Impurity 40 is supplied with detailed characterization data compliant with regulatory guideline. Remibrutinib Impurity 40 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Remibrutinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Remibrutinib Impurity 40

Purchase Remibrutinib Impurity 40

Remibrutinib Impurity 40 suppliers

Remibrutinib Impurity 40 manufacturers

Remibrutinib Impurity 40 price

Order Remibrutinib Impurity 40

Enquire Remibrutinib Impurity 40

Remibrutinib Impurity 40 cost

Remibrutinib Impurity 40 Supplier

Remibrutinib Impurity 40 Distributor

Remibrutinib Impurity 40 for Method Validation

Remibrutinib Reference Standard

Remibrutinib Impurity 40 for ANDA Filing

Remibrutinib Impurity 40 for Forced Degradation Studies

Remibrutinib Impurity 40 Identification Standards

Remibrutinib Impurity 40 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,